Research programme: keratoconjunctivitis therapeutics - Adenovir Pharma

Drug Profile

Research programme: keratoconjunctivitis therapeutics - Adenovir Pharma

Alternative Names: APD-514; Epidemic keratoconjunctivitis therapeutics - Adenovir Pharma; Trisialic acid second generation drug - Adenovir Pharma

Latest Information Update: 28 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adenovir Pharma; Umea University
  • Developer Adenovir Pharma
  • Class Eye disorder therapies; Sialic acids
  • Mechanism of Action Viral protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Infectious keratoconjunctivitis

Most Recent Events

  • 29 Jun 2015 Adenovir Pharma receives grant from Sweden's VINNOVA to develop ADP 514 for Infectious keratoconjunctivitis
  • 29 Jun 2015 Preclinical trials in Infectious keratoconjunctivitis in Sweden (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top